Search

The article discusses the results of a study which showed that patients with chronic hepatitis C who received interferon-based therapy and had sustained virologic response had a better quality of life, presented at the Digestive Disease Week conference held in Orlando, Florida from may 18-21, 2013.

The article discusses Veterans Affairs Puget Sound Health Care System researcher George N. Ioannou's presentation at the American Association for the Study of Liver Diseases' Liver Meeting conference in Washington, D.C., on the treatment of hepatitis C virus coinfection among patients with HIV.

The article discusses researcher Anita Kohli's presentation at the American Association for the Study of Liver Diseases' Liver Meeting 2013 conference in Washington, D.C., focusing on the use of multiple direct-acting antivirals in the treatment of hepatitis C virus infection.

The article discusses the results of the phase 2 trial of an all-oral combination of faldaprevir, deleobuvir, and PPI-668, with and without ribavirin, in patients with hepatitis C virus (HCV) genotype-1a infection as of December 2013.

The article presents the two phase 3 randomized double-blind studies, which showed that a treatment of boceprevir combined with pegylated interferon-ribavirin improved continuous virologic response in patients with hepatitis C and advanced fibrosis and cirrhosis.